Pharsight

1. List of Adhansia Xr drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10512612	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (12 years from now)
US10512613	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (12 years from now)
US10292939	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (12 years from now)
US10449159	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (12 years from now)
US10111839	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (12 years from now)
US10688060	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (12 years from now)
US10507186	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (12 years from now)
US9974752	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (12 years from now)
US10292938	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (12 years from now)
US10568841	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (12 years from now)
US10500162	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Oct, 2035 (12 years from now)
US10722473	PURDUE PHARMA LP	Methods and compositions particularly for treatment of attention deficit disorder	Nov, 2038 (15 years from now)

Do you want to check out ADHANSIA XR patents from before 2022?

Exclusivity	Exclusivity Expiration
M (M)	Jun 28, 2024

Market Authorisation Date: 27 February, 2019

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
25MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
35MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
45MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
55MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
70MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
85MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

ADHANSIA XR family patents

United States

Canada

Australia

Singapore

Japan

Chile

Mexico

Argentina

Brazil

China

South Africa

Israel

Taiwan

Korea, Republic of

Hong Kong

European Union

2. List of Jornay Pm drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10905652	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (8 years from now)
US9028868	IRONSHORE PHARMS	Methods and compositions for treatment of attention deficit disorder	Mar, 2032 (8 years from now)
US9034902	IRONSHORE PHARMS	Methods for treatment of attention deficit hyperactivity disorder	Mar, 2032 (8 years from now)
US8916588	IRONSHORE PHARMS	Methods for treatment of attention deficit hyperactivity disorder	Mar, 2032 (8 years from now)
US9603809	IRONSHORE PHARMS	Methods of treatment of attention deficit hyperactivity disorder	Mar, 2032 (8 years from now)
US10292937	IRONSHORE PHARMS	Methods of treatment of attention deficit hyperactivity disorder	Mar, 2032 (8 years from now)
US10617651	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (8 years from now)
US10881618	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (8 years from now)
US11241391	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (8 years from now)
US11241392	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (8 years from now)
US9498447	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (8 years from now)
US9283214	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (8 years from now)
US9023389	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (8 years from now)
US8927010	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (8 years from now)
US10182995	IRONSHORE PHARMS	Compositions for treatment of attention deficit hyperactivity disorder	Mar, 2032 (8 years from now)

Do you want to check out JORNAY PM patents from before 2022?

Market Authorisation Date: 08 August, 2018

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
20MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
40MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
60MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
80MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
100MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

JORNAY PM family patents

United States

Japan

Australia

European Union

Singapore

China

Denmark

Portugal

Spain

Korea, Republic of

Canada

Mexico

Brazil

South Africa

3. List of Methylin drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7691880	SPECGX LLC	Methylphenidate solution and associated methods of administration and production	Oct, 2024 (1 year, 4 months from now)

Do you want to check out METHYLIN patents from before 2022?

Market Authorisation Date: 19 December, 2002

Treatment: NA

Dosage: SOLUTION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
5 mg/5 mL 10 mg/5 mL	13 Apr, 2010	1	23 Jul, 2010	07 Oct, 2024	Eligible

Strength	Dosage	Availability
5MG/5ML	SOLUTION;ORAL	Prescription
10MG/5ML	SOLUTION;ORAL	Prescription

METHYLIN family patents

United States

Canada

Mexico

China

Australia

Spain

Japan

Austria

European Union

4. List of Quillichew Er drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8202537	NEXTWAVE PHARMS	Modified release formulations containing drug-ion exchange resin complexes	Mar, 2027 (3 years from now)
US8287903	NEXTWAVE PHARMS	Orally effective methylphenidate extended release powder and aqueous suspension product	Feb, 2031 (7 years from now)
US8999386	NEXTWAVE PHARMS	Methylphenidate extended release chewable tablet	Aug, 2033 (10 years from now)
US11633389	NEXTWAVE PHARMS	Methylphenidate extended release chewable tablet	Aug, 2033 (10 years from now)
US9545399	NEXTWAVE PHARMS	Methylphenidate extended release chewable tablet	Aug, 2033 (10 years from now)
US9295642	NEXTWAVE PHARMS	Methylphenidate extended release chewable tablet	Aug, 2033 (10 years from now)
US9844544	NEXTWAVE PHARMS	Methylphenidate extended release chewable tablet	Aug, 2033 (10 years from now)
US11103495	NEXTWAVE PHARMS	Methylphenidate extended release chewable tablet	Aug, 2033 (10 years from now)
US10857143	NEXTWAVE PHARMS	Methylphenidate extended release chewable tablet	Aug, 2033 (10 years from now)
US11103494	NEXTWAVE PHARMS	Methylphenidate extended release chewable tablet	Aug, 2033 (10 years from now)

Do you want to check out QUILLICHEW ER patents from before 2022?

Market Authorisation Date: 04 December, 2015

Treatment: A method of providing a subject with therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet accor...

Dosage: TABLET, EXTENDED RELEASE, CHEWABLE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
20 mg, 30 mg and 40 mg	25 Apr, 2016	1		14 Aug, 2033

Strength	Dosage	Availability
20MG	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	Prescription
30MG	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	Prescription
40MG	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	Prescription

QUILLICHEW ER family patents

United States

Australia

Denmark

Spain

European Union

Canada

Brazil

Israel

China

Russia

Japan

Taiwan

Austria

Korea, Republic of

5. List of Quillivant Xr drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8062667	NEXTWAVE	Modified release formulations containing drug-ion exchange resin complexes	Mar, 2029 (5 years from now)
US9040083	NEXTWAVE	Orally effective methylphenidate extended release powder and aqueous suspension product	Feb, 2031 (7 years from now)
US8563033	NEXTWAVE	Orally effective methylphenidate extended release powder and aqueous suspension product	Feb, 2031 (7 years from now)
US8956649	NEXTWAVE	Orally effective methylphenidate extended release powder and aqueous suspension product	Feb, 2031 (7 years from now)
US8465765	NEXTWAVE	Orally effective methylphenidate extended release powder and aqueous suspension product	Feb, 2031 (7 years from now)
US8778390	NEXTWAVE	Orally effective methylphenidate extended release powder and aqueous suspension product	Feb, 2031 (7 years from now)
US8287903	NEXTWAVE	Orally effective methylphenidate extended release powder and aqueous suspension product	Feb, 2031 (7 years from now)

Do you want to check out QUILLIVANT XR patents from before 2022?

Market Authorisation Date: 27 September, 2012

Treatment: Treating a patient having a condition susceptible to treatment with methylphenidate, such as adhd, by administering the formulation recited in claims 1 or 2; Method of treating attention deficit hyper...

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL